LONDON, England and DUBLIN, Ireland, January 11 /PRNewswire-FirstCall/
- Trading Profitability in Line With Analysts Expectations
- Significant Technological and Commercial Progress in Nanopeutics(TM)
- Nanopeutics Entry Into the Global Consumer Woundcare, Military and
the Global Blood Filtration Markets
- Final Stage Negotiations With a North American Based CVH Specialist
to Enter the Global Nutrition Market With a Range of Patented CVH
Functional Food and Bio-Active Technologies
Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"),
(AIM:AP.L), the Medical Technology Company focussed on the Woundcare,
Oralcare and Cardiovascular Health markets, today announces that following
the commencement of first licence revenue in quarter four, analysis of
initial consolidated numbers indicate that full year 2006 numbers will be
in line with analysts profitability expectations.
Formal full year preliminary results are scheduled for release in early
Highlights of the quarter include:
- Nanopeutics, the specialist subsidiary dedicated to the
commercialisation of Nanospider(TM) technology for the global woundcare
markets, agrees a license bearing exclusive nanotechnology development
partnership with a global leader in professional woundcare. The concept
development project is ahead of agreed schedule and the successful
conclusion to the development work will lead to an exclusive global royalty
bearing licence and supply agreement for Nanospider(TM) based technology
and specialist products.
- Nanopeutics is currently finalizing negotiations on similar exclusive
concept development agreements with existing companies in a number of other
woundcare and related markets; specifically the global consumer woundcare,
the military and the global blood filtration markets. Separate
announcements are expected later this quarter.
- Following last quarters preclinical trials confirming wound and
dermal healing properties in a number of finalised product delivery systems
Alltracel are now in late stage negotiations with a specialist
anti-microbial supplier for the in-licencing of a novel anti-microbial
technology for exclusive commercialization rights for the global woundcare
markets: consumer, professional and military for textile, non-textile and
- Following successful combination trials earlier this year and last
quarter's successful development of a highly soluble derivative of
Alltracel's patented cardiovascular health benefiting bioactive; subsequent
commercialisation negotiations are concluding with one of the combination
trial partners, a North American based CVH specialist, for the
establishment of a technology and business development alliance to enter
the global nutrition market with a range of patented CVH functional food
and bio-active technologies. A separate statement is expected shortly.
- Oralcare- continued strong oral care trade performance with business
wins in all major markets
Alltracel CEO Tony Richardson commented:
"We are pleased at the significant progress this quarter both in terms
of financial performance, technology breakthroughs and significant
commercial developments. Subject to final confirmation and audit we remain
comfortable with analysts' expectations of the business reaching full year
profitability for the year 2006.
Our oral care business continues to perform strongly and following the
cessation of our exploratory discussions last month concerning the
potential disposal of this division, we have progressed plans to grow this
business via further investment and potential M&A activity.
This quarter saw our first licence revenue and we are confident of a
continued growth in sustainable profitable revenue as we transition the
business to more of a licence and technology transfer business model rather
than one focussed on product revenue alone."
For Further Information Contact:
Dublin: Denise Cronin Alltracel: +353-1-235-2162
London: Deborah Scott Financial Dynamics: +44-(0)207-831-3113
New York: Sean Leous Financial Dynamics: +1-212-850-5626
Notes to Editors follow:
Alltracel (AIM: AP.L) (www.alltracel.com) Alltracel Pharmaceuticals Plc
("Alltracel") is a Medical Technology Company focussed on the Woundcare,
Oralcare and Cardiovascular Health markets.
With corporate headquarters in Dublin, Ireland; Alltracel has a
commercial office in London, England; R&D subsidiary in the Czech Republic
and manufacturing facilities in Shenzhen, China.
Alltracel was founded in 1996 and listed on London's Alternative
Investment Market in July 2001.
Alltracel' has a number of patents in the areas of polysaccharide
manipulation and PTFE processes and products as well as a significant
collaborative R&D programme in place focussed on its markets.
In the consumer Woundcare market m-doc(TM) (Micro Dispersed Oxidized
Cellulose; (www.m-doc.com)) is the trading name given to Alltracel's
patented technology which is proven as an effective and efficient
haemostatic (blood-stopping) agent and is currently being marketed as the
leading stops bleeding ingredient brand within recognized woundcare, and
relevant first-aid brands worldwide.
Alltracel's specialist Nanotechnology subsidiary Nanopeutics(TM)
(www.nanopeutics.net) is headquartered in Liberec in the Czech Republic and
is dedicated to the commercialisation of Nanospider(TM) technology for the
global professional and consumer woundcare markets.
Within the Cardiovascular Health market Alltracel
(www.alltracelcvh.com) has developed a novel bioactive compound that,
following over two years of scientific research including in vitro,
pre-clinical and clinical trials, indicates cardiovascular health (CVH)
benefits on its own and in combination with existing CVH products.
The end result is a pioneering, value-adding bioactive that can enhance
and differentiate current cardiovascular health products and that can add
benefit to current non-health benefiting nutritious finished foods.
m-doc(TM) is a trademarks of Alltracel Pharmaceuticals PLC.
Nanospider(TM) and Nanopeutics(TM) are trademarks controlled by
SOURCE Alltracel Pharmaceuticals Plc.